



CANCER PREVENTION & RESEARCH INSTITUTE OF TEXAS

Award ID:
RP170006

Project Title:
Investigational New Drug Production Core Facility at Scott & White Cancer
Research Int

Award Mechanism:
Core Facilities Support Awards - Competitive Renewal

Principal Investigator:
Woo, Jung H

Entity:
Scott and White Healthcare

Lay Summary:

To improve cancer therapy, scientific discoveries from cancer research must be translated into practical applications, such as new drug development. New drugs need to be produced in specialized facilities, with qualified equipment and trained personnel, for compliance with FDA regulations. For these reasons, the limiting factor in new drug production is often related to production costs.

The main goal of the Cancer Research Institute (CRI) Core Facility is to provide investigators with new drugs for efficacy and safety testing in all types of cancer patients. There is a growing need by investigators in Texas and beyond for producing investigational new drugs. These new drugs show anti-tumor efficacy in tissue culture tests and/or in cancer model animals. The CRI at Scott & White is housed in 17,000 square feet, and includes multiple laboratories and two Good Manufacturing Practice drug manufacturing suites. To expand production capability for efficiently responding to the growing drug production need, the conversion of a vacant 5 million dollar GMP clean space (7,500 sq-ft) into a GMP 3 suite for drug production in mammalian cells is planned. In this regard S&W will continue to make a strong commitment to the CRI Core Facility by providing the new GMP clean space with renovation expenses, extensive equipment and facility maintenance support, and operating budget support.

We are submitting this proposal to seek out the necessary equipment for the new GMP 3 suite and quality improvement of existing GMP suites, partial salary support for core staff, and some supplies support for subsidizing costs for production of promising drug candidates. With the support of CPRIT, the production costs can be significantly reduced. As a result, many investigators at various career-stages can utilize the Core Facility for drug production. Increased testing of new drugs in humans will strengthen cancer research in Texas and may provide better therapies to cancer patients.